Month: September 2016

13 Sep 2016


Triclinium will for the third time participate in the annual VPM Days Conference in Hannover, Germany on 15th – 16th September 2016.

VPM is Vakzine Projekt Management, a public–private partnership venture founded jointly by the German Federal Ministry of Education and Research and the Braunschweig-based Helmholtz Centre for Infection Research in 2002.  Since 2009, Triclinium has collaborated with VPM as the managing CRO for three Phase I and II trials conducted in South Africa with their novel tuberculosis vaccine, VPM1002.

The VPM Days annual meeting brings together a wide group of organisations and academics involved in translation research and development.  Triclinium’s Managing Director will present a paper entitled “The regulatory landscape in South Africa and neighbouring countries: updates, challenges and opportunities.” Triclinium has become a regular contributor to this forum.  Mr. Strugo was also an invited presenter in 2015 preceded in 2012 by Tracy Southwood, at the time Triclinium’s Project Manager for VPM’s Phase I trial and currently Head of Business Development.

VPM1002 is a recombinant BCG vaccine co-developed by VPM and the Max Planck Society.  It was recently out-licensed to Serum Institute of India Ltd, the world’s largest vaccine manufacturer, which will also be represented at the VPM Days this year.  The full conference programme is at

06 Sep 2016

New HPV Guidelines supported by American Cancer Society

The US government’s recommendation to vaccinate all pre-teens against the human papilloma virus, has received support from the American Cancer Society.

According to Debbie Saslow, the cancer society’s director of cancer control intervention for HPV vaccination and women’s cancers, “HPV vaccination has the potential to prevent tens of thousands of cancers and hundreds of thousands of pre-cancers each year. It is critical that all stakeholders — families, health care providers, and others — make HPV vaccination a priority, so that prevention of the vast majority of cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers can become a reality.”

After recent studies indicated that the vaccine can protect both males and females, the Centre for Disease Control’s Advisory Committee on Immunization Practices, decided to also include males to the list of recipients of the vaccine.

For more on this, please go to: